Proteomedix announces commercial launch of its blood-based test for prostate cancer


Ten year after the start of the company, Proteomedix‘ test for cancer diagnosis is now commercially available in Europe. The announcement of the launch follows a thorough clinical validation in which the convenient blood test, optimized for maximum sensitivity for prostate cancer, demonstrated an accuracy that is superior to any other in-vitro diagnostic method of prostate cancer diagnosis.


Proteomedix announced today the market entry of Proclarix. The test combines proprietary biomarkers and a risk score with a proprietary algorithm that accurately identifies an individual patient’s risk for clinically significant prostate cancer.

With its high level of performance, the new risk score provides a reliable and convenient method to complement PSA (Prostate-Specific Antigen) testing in prostate cancer diagnosis. Proclarix has the potential to significantly reduce the number of biopsies needed to detect clinically relevant prostate cancer. The negative predictive value (NPV) of the test – a commonly used measure for the likelihood of actually not having cancer when a test is negative – was found to be 95% in a large study of 955 subjects collected from two different hospital cohorts evaluating its performance

According to the World Health Organization, there were about 450000 diagnosed cases of prostate cancer and over 105000 deaths from prostate cancer in 2018 in Europe. Prostate cancer remains the second-leading cause of cancer death in men in Europe.

Proteomedix was founded in 2010 as a spin-off company of ETH Zurich. As a medical need-oriented organization with a strong focus on research and development, it relies on a powerful network of clinicians, IVD experts, pharmacists and marketers. Proteomedix is located at the Bio-Technopark in Zurich, Switzerland.

(Press release / SK)

Picture: Chokniti Khongchum / Pixabay